The Party Central Committee and the State Council have always attached great importance to raising the people's health level and promoting the development of medical and health services. General Secretary Hu Jintao clearly stated in the report of the 17th National Congress of the Communist Party of China: "To establish a basic medical and health system," and to "build a public health service system, medical service system, medical security system, and drug supply guarantee system covering urban and rural residents. Provide safe, effective, convenient, and affordable medical and health services." In accordance with the new requirements set by the party’s 17th National Congress to achieve the goal of building a well-off society in an all-round way, and in accordance with the strategic needs of China's pharmaceutical and health development, the Party Group of the Ministry of Health proposed the concept of formulating a "Healthy China 2020" strategic plan. The “Healthy China 2020†strategy is a national-level medium- and long-term strategic plan for health development. To formulate this plan is to guarantee the realization of the goal of building a well-to-do society in an all-round way, to achieve the goal of enjoying basic medical and health services for all, and to improve the health quality of the entire nation. Important guarantee.
To ensure the smooth start and steady progress of the formulation of the "Health China 2020" strategic plan, the Ministry of Health organized relevant experts to set up a number of research groups to conduct preliminary studies on planning and formulation. The "Drug Policy Research Group" is a very important part of this. With the entrustment of Comrade Chen Xi and the Ministry of Health, I, as the chief expert of the Pharmaceutical Policy Research Group, is responsible for organizing the policy research on medicines and medical devices, and in particular on the national drug policy, basic drug system, and industrial policy. The national drug policy is an indispensable part of the national health policy. It is directly related to the health of the people and it is also related to economic growth, social progress and stability of the country. It can be said that the drug production at the national level has Circulation, innovation, and development policies and systems have no way of talking about the healthy development and deepening of reforms in the health sector.
The "Drug Policy Research Group" is divided into 8 sub-topics, and the national pharmaceutical industry policy is one of them. We believe that in the study of the Strategic Plan for Healthy China 2020, we must put forward the policy research that promotes the healthy development of China's pharmaceutical industry as an important issue. We must realize that the pharmaceutical industry is more than just a simple drug production problem. Once a major epidemic, a major disaster, or even a war occurs, the nation can rely on the national pharmaceutical industry. Therefore, I believe that the national pharmaceutical industry is in essence a healthy development. , is a major issue involving national strategic security. We all know that industrial policy determines the orientation and direction of an industry in the country’s economic life; it determines the direction of specific policies in the process of industrial development. China is a rapidly growing large developing country. With the improvement of people's living standards, the demand for health has also greatly increased. In a certain sense, without the healthy development of the pharmaceutical industry, there will be no healthy development of the national medical and health services. China has become one of the fastest-growing pharmaceutical markets in the world. However, unlike the fast-growing pharmaceutical market, China’s national pharmaceutical industry has never been detached from the embarrassing situation of “imitation-basedâ€. Although there are a large number of companies, they are large. Most of the large-scale modern pharmaceutical industry groups do not have the scale and the industrial standards and variety benefits that are in line with international standards, especially the weak ability of independent innovation, the lack of competitiveness of products, and the meager profits. Many units are in dilemma.
With the globalization of the economy and the internationalization of domestic competition, it is of great significance to promote the healthy development of China's national pharmaceutical industry and promote China's advancement from a large pharmaceutical country to a powerful pharmaceutical country. First of all, promoting the healthy development of the national pharmaceutical industry is an important guarantee for achieving primary health care and meeting the basic health needs of the people. As a large developing country with a population of 1.3 billion, in the current situation that the state’s financial resources and residents’ individual fund-raising capacity are relatively limited, it is necessary to realize the goal of health care for all and to meet the basic drug demand of the masses and must rely on the production of the national pharmaceutical industry. The basic medicine. The Party Central Committee and the State Council attach great importance to the healthy development of the pharmaceutical industry. We should note that General Secretary Hu Jintao clearly stated in the report of the 17th National Congress of the CPC: “Establish a national basic medicine system to ensure basic medication for the masses. Support Chinese medicine And the development of ethnic medicine." This is an unreserved request for our responsibility. At the same time, it also gives us a good job in our own work and further enhances the confidence of the pharmaceutical industry.
Representatives of the pharmaceutical regulatory agencies, research institutes, industry associations, and pharmaceutical companies in particular, should work together to discuss how the pharmaceutical industry in China should develop and how to assume the responsibility of the Chinese nationals for health drug use. How to ensure the quality and safety of pharmaceuticals at the same time, We must resolutely ensure the strategic safety of national drugs; how the state should position the pharmaceutical industry and how to adopt practical and feasible policies to promote the development of China's pharmaceutical industry to independent innovation and healthy development. Independent innovation is the biggest gap between our ethnic pharmaceutical companies and the multinational pharmaceutical giants, and it is also our weakest link. Now the country attaches great importance to pharmaceutical innovation and lists major new drug creation as one of the country's 16 major science and technology projects. One of the important tasks in the special project is to promote the establishment of innovative drug incubation bases, large variety development, and major key technology research. We hope that through the implementation of special projects, we will set up a number of innovative drug incubation bases with enterprises as the mainstay, combined production, education and research. We will make big drugs bigger and truly improve our technological innovation capabilities.
I believe that through the development of national drug policy research, the establishment and improvement of relevant pharmaceutical policies in line with China's national conditions such as the essential drug system, drug industry policy, and drug innovation mechanism will surely further promote the healthy development of China's pharmaceutical and health industry and will also promote The leap-forward development of China's national medicine industry has truly transformed China's great transition from a pharmaceutical country to a pharmaceutical country
To ensure the smooth start and steady progress of the formulation of the "Health China 2020" strategic plan, the Ministry of Health organized relevant experts to set up a number of research groups to conduct preliminary studies on planning and formulation. The "Drug Policy Research Group" is a very important part of this. With the entrustment of Comrade Chen Xi and the Ministry of Health, I, as the chief expert of the Pharmaceutical Policy Research Group, is responsible for organizing the policy research on medicines and medical devices, and in particular on the national drug policy, basic drug system, and industrial policy. The national drug policy is an indispensable part of the national health policy. It is directly related to the health of the people and it is also related to economic growth, social progress and stability of the country. It can be said that the drug production at the national level has Circulation, innovation, and development policies and systems have no way of talking about the healthy development and deepening of reforms in the health sector.
The "Drug Policy Research Group" is divided into 8 sub-topics, and the national pharmaceutical industry policy is one of them. We believe that in the study of the Strategic Plan for Healthy China 2020, we must put forward the policy research that promotes the healthy development of China's pharmaceutical industry as an important issue. We must realize that the pharmaceutical industry is more than just a simple drug production problem. Once a major epidemic, a major disaster, or even a war occurs, the nation can rely on the national pharmaceutical industry. Therefore, I believe that the national pharmaceutical industry is in essence a healthy development. , is a major issue involving national strategic security. We all know that industrial policy determines the orientation and direction of an industry in the country’s economic life; it determines the direction of specific policies in the process of industrial development. China is a rapidly growing large developing country. With the improvement of people's living standards, the demand for health has also greatly increased. In a certain sense, without the healthy development of the pharmaceutical industry, there will be no healthy development of the national medical and health services. China has become one of the fastest-growing pharmaceutical markets in the world. However, unlike the fast-growing pharmaceutical market, China’s national pharmaceutical industry has never been detached from the embarrassing situation of “imitation-basedâ€. Although there are a large number of companies, they are large. Most of the large-scale modern pharmaceutical industry groups do not have the scale and the industrial standards and variety benefits that are in line with international standards, especially the weak ability of independent innovation, the lack of competitiveness of products, and the meager profits. Many units are in dilemma.
With the globalization of the economy and the internationalization of domestic competition, it is of great significance to promote the healthy development of China's national pharmaceutical industry and promote China's advancement from a large pharmaceutical country to a powerful pharmaceutical country. First of all, promoting the healthy development of the national pharmaceutical industry is an important guarantee for achieving primary health care and meeting the basic health needs of the people. As a large developing country with a population of 1.3 billion, in the current situation that the state’s financial resources and residents’ individual fund-raising capacity are relatively limited, it is necessary to realize the goal of health care for all and to meet the basic drug demand of the masses and must rely on the production of the national pharmaceutical industry. The basic medicine. The Party Central Committee and the State Council attach great importance to the healthy development of the pharmaceutical industry. We should note that General Secretary Hu Jintao clearly stated in the report of the 17th National Congress of the CPC: “Establish a national basic medicine system to ensure basic medication for the masses. Support Chinese medicine And the development of ethnic medicine." This is an unreserved request for our responsibility. At the same time, it also gives us a good job in our own work and further enhances the confidence of the pharmaceutical industry.
Representatives of the pharmaceutical regulatory agencies, research institutes, industry associations, and pharmaceutical companies in particular, should work together to discuss how the pharmaceutical industry in China should develop and how to assume the responsibility of the Chinese nationals for health drug use. How to ensure the quality and safety of pharmaceuticals at the same time, We must resolutely ensure the strategic safety of national drugs; how the state should position the pharmaceutical industry and how to adopt practical and feasible policies to promote the development of China's pharmaceutical industry to independent innovation and healthy development. Independent innovation is the biggest gap between our ethnic pharmaceutical companies and the multinational pharmaceutical giants, and it is also our weakest link. Now the country attaches great importance to pharmaceutical innovation and lists major new drug creation as one of the country's 16 major science and technology projects. One of the important tasks in the special project is to promote the establishment of innovative drug incubation bases, large variety development, and major key technology research. We hope that through the implementation of special projects, we will set up a number of innovative drug incubation bases with enterprises as the mainstay, combined production, education and research. We will make big drugs bigger and truly improve our technological innovation capabilities.
I believe that through the development of national drug policy research, the establishment and improvement of relevant pharmaceutical policies in line with China's national conditions such as the essential drug system, drug industry policy, and drug innovation mechanism will surely further promote the healthy development of China's pharmaceutical and health industry and will also promote The leap-forward development of China's national medicine industry has truly transformed China's great transition from a pharmaceutical country to a pharmaceutical country
When you need truly industrial inkjet coders, Chinahae is ready with the right products and technical service for your application. A Lot Coder, Batch Coder or Date Coder from Superior always offers the greatest dependability and value on the market.
For your Date Coding needs, Chinahae delivers rock-bottom pricing on only the most advanced, low maintenance industrial inkjet coders. We are always ready to serve you with all the support you need for your application.
We have DOD, CIJ, TIJ different type Inkjet printers, high resolution inkjet coder can be used in food, beverage, building material, pipe, cable, pharmaceutical, electronic etc. field
Inkjet Coding Printer,Industrial Inkjet Printer,Continuous Inkjet Printer,Handheld Inkjet Printer,Date Coding Printer,Inkjet Coder Machine,Inkjet Coding Systems,Inkjet Code Printer,Inkjet Date Code Printer
Wuhan HAE Technology Co., Ltd. , https://www.whuvwallprinter.com